AC
IOVA icon

Athanor Capital’s Iovance Biotherapeutics IOVA Stock Holding History

Athanor Capital’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-12,089
Closed -$383K – 591
2021
Q1 		$383K Sell
12,089
-23,327
-66% -$967K 0.01% 536
2020
Q4 		$1.64M Buy
+35,416
New +$1.41M 0.04% 224
2020
Q3 		– Sell
-36,895
Closed -$1.01M – 605
2020
Q2 		$1.01M Buy
+36,895
New +$1.21M 0.05% 188
2020
Q1 		– Sell
-35,200
Closed -$974K – 246
2019
Q4 		$974K Buy
35,200
+3,800
+12% +$86.4K 0.04% 150
2019
Q3 		$571K Buy
+31,400
New +$694K 0.04% 145

Other funds holding IOVA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Athanor Capital's IOVA Position: Q2 2021 in Review

Athanor Capital sold out of Iovance Biotherapeutics (IOVA) in Q2 2021, closing a stake of 12,089 shares — an estimated $383K sold.

Athanor Capital first reported a position in IOVA in Q3 2019 and held it in 5 quarters. The position peaked at $1.64M in Q4 2020. 234 funds tracked by Wall St. Rank hold IOVA as of Q2 2021.

  • Athanor Capital reported no remaining Iovance Biotherapeutics position as of Q2 2021 after selling out during the quarter.
  • Athanor Capital sold 12,089 Iovance Biotherapeutics shares in Q2 2021, an estimated $383K.
  • Athanor Capital first reported a position in Iovance Biotherapeutics in Q3 2019 and held it in 5 quarters.
  • Athanor Capital's Iovance Biotherapeutics position peaked at $1.64M in Q4 2020.
  • 234 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2021.

Based on Athanor Capital's 13F filing for Q2 2021, filed 16 Aug 2021.